| Autor: |
Musso C; Servicio de Endocrinología y Diabetología, Hospital César Milstein, Buenos Aires, Argentina.; Servicio de Diabetología, Fundación Favaloro, Buenos Aires, Argentina., Capurro L; Servicio de Endocrinología y Medicina Nuclear, Hospital Italiano de Buenos Aires, Argentina., Mingote E; Servicio de Endocrinología y Diabetología, Hospital César Milstein, Buenos Aires, Argentina., Forti L; Departamento Médico Sanofi, Buenos Aires, Argentina., Guaita MS; Departamento Médico Sanofi, Buenos Aires, Argentina. E-mail: mariasilvina.guaita@sanofi.com. |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Medicina [Medicina (B Aires)] 2019; Vol. 79 (4), pp. 241-250. |
| Abstrakt: |
Type 2 diabetes is a chronic, progressive disease with increasing prevalence and still late diagnostic. This leads to an increase in the incidence of chronic complications, with signifi cantly increasing health costs. There is also a delay in the onset of insulin therapy in patients with type 2 diabetes for causes related to both patients and physicians. Despite advances in treatment, a low proportion of patients achieve adequate glycemic control. The high hypoglycemia prevalence, consequence of insulin, has led to the development of a new generation long-acting basal insulins to achieve a more stable and prolonged action profile, reducing the variability and risk of hypoglycemia. The EDITION program evaluated the efficacy and safety of glargine U300 compared to glargine U100 in patients with type 1 and 2 diabetes at different stages of the disease. Gla-300 is a new formulation of insulin glargine which has a more stable and prolonged pharmacokinetic and pharmacodynamic profile. Gla-300 demonstrated efficacy and tolerability comparable to glargine U100, with a significant decrease in the risk of hypoglycemia, at night and in 24 hours, providing greater flexibility in the injection schedule, with a window of 6 hours. No increase in weight was observed compared to glargine U100. Bright study (2018) compared glargine U300 vs. degludec U100, demonstrating greater benefit in relation to the risk of hypoglycemia with Gla-300 during titration period. Gla-300 is a last-generation basal insulin, available to improve metabolic control, with a lower risk of hypoglycemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
